Equity Offering

September 05, 2019

Esmo 2019 preview – Parps on parade

Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.

G1 makes the most of trilaciclib's unclear survival benefit

G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.

August 13, 2018

Data point - Orchard growth

July 09, 2018

The venture money keeps flowing for biopharma

Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.

May 18, 2018

Snippet roundup: One in, one out in Alzheimer's, but for Lilly oncology is bigger

May 11, 2018

Snippet roundup: Pivotal fluffs from Faron and Fasenra

May 04, 2018

Snippet roundup: The good times roll for Moderna, but Mallinckrodt and Smith & Nephew flag

March 23, 2018

Snippet roundup: Funding boosts the US NIH and could spawn a UK ubercorn

March 21, 2018

Proteostasis’s credibility slowly unwinds

March 16, 2018

Ionis gives a lesson in financial engineering

February 28, 2018

Astra finds no fit for rare diseases in latest big pharma spin-out

Load More